Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 11, 2016 8:57 AM ET

Pharmaceuticals

Company Overview of Braeburn Pharmaceuticals, Inc.

Company Overview

Braeburn Pharmaceuticals, Inc. develops and commercializes medical products. It develops Probuphine for the treatment of adult patients with opioid dependence. The company also develops and commercializes products for the treatment of schizophrenia and other serious psychiatric disorders. Braeburn Pharmaceuticals, Inc. was founded in 2012 and is based in New York, New York.

New York, NY 

United States

Founded in 2012

Phone:

609-751-5375

Key Executives for Braeburn Pharmaceuticals, Inc.

Chief Executive Officer and President
Age: 52
Global Head of Quality Assurance and Quality Control
Age: 58
Executive Vice President of Clinical and Regulatory Affairs
Head of Commercialization for Apple Tree Partners and Partner of Apple Tree Partners
Age: 55
Vice President of Supply Chain
Age: 61
Compensation as of Fiscal Year 2015.

Braeburn Pharmaceuticals, Inc. Key Developments

Braeburn Pharmaceuticals and Knight Therapeutics Enter into Canadian Sublicense Pact for PROBUPHINE

Braeburn Pharmaceuticals and Knight Therapeutics reported that they have entered into an agreement whereby Knight received the exclusive rights to commercialize PROBUPHINE in Canada. PROBUPHINE is an investigational subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment, promoting patient compliance and retention as well as helping to prevent accidental paediatric exposure. Under the terms of this sublicense agreement, Knight will also handle all ongoing regulatory and commercial activities for PROBUPHINE in Canada.

Braeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense Agreement for PROBUPHINE

Braeburn Pharmaceuticals, Inc. and Knight Therapeutics Inc. announced that they have entered into an agreement whereby Knight received the exclusive rights to commercialize PROBUPHINE in Canada. PROBUPHINE is an investigational subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment, promoting patient compliance and retention as well as helping to prevent accidental paediatric exposure. Under the terms of this sublicense agreement, Knight will also handle all ongoing regulatory and commercial activities for PROBUPHINE in Canada.

Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals Receives Approve to Probuphine from Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration

Titan Pharmaceuticals, Inc. and partner Braeburn Pharmaceuticals announced that the Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) voted 12 to 5 in favor of approving Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction, in stable patients receiving 8mg or less per day of buprenorphine. The Committee's vote followed presentation and discussion of data regarding Probuphine's efficacy, safety, and risk-benefit profile. The New Drug Application (NDA) for Probuphine was resubmitted to the FDA in August 2015, and accepted by the FDA in September 2015.

Similar Private Companies By Industry

Company Name Region
Graceway Pharmaceuticals, LLC United States
PepTech Corp. United States
Blessed Herbs, Inc. United States
Satiogen Pharmaceuticals, Inc. United States
ViaCell Endocrine Science, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
May 1, 2015
Endo Pharmaceuticals Inc., Antipsychotic Risperidone
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Braeburn Pharmaceuticals, Inc., please visit braeburnpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.